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Role of the Waist/Height Ratio
in the Cardiometabolic Risk Assessment
of Children Classified by Body Mass Index
Michael Khoury, MD, Cedric Manlhiot, BSC, Brian W. McCrindle, MD, MPH
Toronto, Canada
Objectives The aim of this study was to determine the utility of waist/height ratio (WHtR) in the specification of cardiometa-
bolic risk in children already stratified by body mass index (BMI).
Background Reflective of its association with cardiometabolic risk, BMI is a commonly used indirect indicator of adiposity in
children. The WHtR, a marker of central adiposity, has been advocated as a possibly superior indicator of cardio-
metabolic risk.
Methods Cross-sectional analysis of 5 National Health and Nutrition Examination Surveys from 1999 to 2008 (ages 5 to
18 years of age). The BMI percentile categories (normal, overweight, and obese) were further stratified on the
basis of WHtR (0.5, 0.5 to 0.6, 0.6). Outcome measures were lipid and glycemic profiles, C-reactive pro-
tein, liver transaminases, prevalence of hypertension, and metabolic syndrome.
Results Data were available for 14,493 subjects. Overweight and obese subjects with a WHtR 0.5 had a cardiometa-
bolic risk approaching that of subjects with a normal BMI percentile category. Increasing WHtR was significantly
associated with increased cardiometabolic risk in overweight and obese subjects, with the greatest associations
observed in the obese population. Of obese subjects with WHtR 0.6, 26% had elevated non–high-density lipo-
protein levels, 18% had elevated C-reactive protein levels, 69% had an elevated homeostatic model
assessment–insulin resistance, and 32% had metabolic syndrome.
Conclusions The WHtR further specifies cardiometabolic risk within classifications stratification on the basis of BMI percen-
tile. A significant proportion of obese children with increased WHtRs have abnormal cardiometabolic risk factor
levels. The WHtR should be included in the routine screening and assessment of overweight and obese chil-
dren, and those with an elevated WHtR should undergo a further cardiometabolic risk assessment. (J Am
Coll Cardiol 2013;62:742–51) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.01.026Childhood overweight and obesity is associated with an
increased prevalence of numerous cardiometabolic risk fac-
tors, including hypertension, hypercholesterolemia, and
type 2 diabetes (1–3). The atherosclerotic process begins in
childhood, and cardiometabolic risk in these early years
tracks into adulthood, potentially resulting in early cardio-
vascular disease events (4,5). Over recent decades, a general
trend of increased cardiometabolic risk factors abnormalities
among children has been observed (6). Body mass index
(BMI) (kilograms/square millimeters) is a commonly used
surrogate measure of adiposity in children. The Interna-
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24, 2012, accepted January 8, 2013.tional Obesity Task Force (7), the U.S. Centers for Disease
Control and Prevention (8), and the World Health Orga-
nization (9) have formulated population-based age- and
sex-specific normal distributions for BMI. It is an estab-
lished correlate of numerous adiposity-related cardiometa-
bolic risk factors in the pediatric population (10,11), and
numerous committees and organizations have endorsed its
use (7,8,12,13). However, BMI by definition cannot distin-
guish between fat and fat-free mass. Therefore, an elevated
BMI might not necessarily reflect increased adiposity
(14–16).
Excessive central adiposity has been shown to be partic-
ularly pathogenic through the development of adiposopathy
(17). The waist/height ratio (WHtR) (waist circumference
divided by height, both measured in centimeters) has been
advocated as an effective and convenient measure of central
adiposity that could potentially be superior to BMI alone in
determining cardiometabolic risk (18–22). However, stud-
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specifically by subject populations that are not diverse and
the lack of assessment of inflammatory markers to further
explore the impact of adiposopathy in central adiposity.
Therefore, through the use of a large and diverse subject
population and the incorporation of inflammatory markers,
we sought to determine the clinical utility of the WHtR in
further specifying the cardiometabolic risk assessment of
children already categorized by BMI.
Methods
National Health and Nutrition Examination Survey.
Data for this study were obtained from 5 National Health and
Nutrition Examination Surveys (NHANES) between the
years 1999 and 2008 (representing 5 2-year cycles) (23) for
subjects 5 to 18 years of age. The NHANES surveys are
complex multi-stage area probability samples of the U.S.
non-institutionalized population, designed to be represen-
tative of the general U.S. population. It is conducted by the
National Center for Health Statistics of the Centers for
Disease Control. To produce reliable statistics, the survey
oversamples certain populations, including African Ameri-
cans and Hispanics. The survey includes a physical exami-
nation and blood sampling for various laboratory measures.
Blood samples are taken from all but the very young.
Fasting, although encouraged, was not mandatory for chil-
dren. The NHANES 1999 to 2008 surveys underwent
ethics approval by the National Center for Health Statistics
Institutional Review Board and Research Ethics Board.
Informed consent was obtained directly from participants 12
years of age and older, whereas written assent was obtained
for children 7 to 11 years of age. Written parental consent
was obtained for all children 18 years of age.
Anthropometric measurements. Standing height was
measured with a stadiometer with a fixed vertical backboard
and an adjustable headpiece. Weight was obtained with a
digital weight scale with the subject in a standard examina-
tion gown (23). Height and weight measurements were then
converted to age- and sex-adjusted BMI percentiles and
z-scores with the World Health Organization growth
standards (9). Subjects were categorized, on the basis of
their BMI percentile, as overweight (85% to 95%) and
obese (95%) (9).
Waist circumference was measured to the nearest 0.1 cm
at the end of a normal expiration with a steel measuring tape
placed at the top of the iliac crest, with the patient in a
standing position. The WHtR was calculated (waist cir-
cumference in centimeters divided by height in centimeters)
and classified into 3 categories (0.5, 0.5 to 0.6, 0.6).
hese categories were selected to provide similar categori-
ation as a previous study involving WHtR (24). The
HtR category and BMI category were combined to form
9-category variable. There were some groups with too few
ubjects to allow for adequate statistical analysis. As such,
he 4 subjects with BMI85% and WHtR0.6 and the 13 tubjects with BMI 85% to95%
nd WHtR0.6 were combined
ith the 1,437 subjects with
MI 95% and WHtR 0.6.
hese specific combinations
ere chosen to maintain subjects
ith WHtR 0.6 in 1 group.
ipid and glycemic profile, in-
ammation. Patients were con-
idered to be fasting if they re-
orted at least 12 h of fasting
efore blood sampling. Com-
lete lipid profile was obtained,
ncluding total cholesterol (TC),
igh-density lipoprotein cholesterol
HDL), triglyceride (TG), low-
ensity lipoprotein (LDL) (calcu-
ated with the Friedewald calcula-
ion: LDLTCHDL [TG/
]) (25), and non–HDL-cholesterol. The ratios of HDL to
C and TG to HDL were calculated. Values for LDL, TG,
nd TG/HDL ratio are reported only for patients with
asting samples. The TC, HDL, non-HDL, and HDL/TC
re reported for all patients and separately for the subgroup
ith fasting samples. Non-fasting TC was considered to be
orderline-high if 4.4 to5.2 mmol/l (170 to200 mg/dl)
and high if 5.2 mmol/l (200 mg/dl) (26). Non-fasting
non-HDL cholesterol was considered to be borderline-high
if 3.10 to 3.75 mmol/l (120 to 145 mg/dl) and high if
3.75 mmol/l (145 mg/dl) (26). Fasting TG levels 1.7
mol/l (150 mg/dl) were considered elevated (26).
Fasting glucose and insulin were measured, with glucose
alues 6.1 mmol/l (110 mg/dl) (26) and insulin values
118 pmol/l (17 IU/ml, reference value used by our
academic institution, on the basis of an internal study)
considered elevated. Insulin resistance was quantified with
the homeostatic model assessment (HOMA-IR), with fast-
ing plasma glucose and insulin measurements (HOMA-IR 
[glucose  insulin]/22.5). A value of 3.16 was considered
abnormal (27). Hemoglobin A1c was measured as a surro-
gate marker of blood glucose control, with values 6.5%
onsidered abnormal (28).
Degree of background inflammation was measured by
evel of C-reactive protein (CRP), measured through an
ltra-sensitive assay. Values 0.7 to3 mg/l were considered
o be mildly elevated, and those3 mg/l were considered to
e elevated (29). Both aspartate aminotransferase and ala-
ine aminotransferase were used as surrogate markers of
iver inflammation. For both measures, values40 U/l were
onsidered abnormal (30).
lood pressure. Replicated measurements were used to
btain systolic and diastolic blood pressure levels. Up to 4
onsecutive blood pressure readings were obtained after the
aximum inflation level was determined, and the subject
ested quietly in a sitting position for 5 min. Mean values of
Abbreviations
and Acronyms
BMI  body mass index
CRP  C-reactive protein
HDL  high-density
lipoprotein
HOMA-IR  homeostatic
model assessment of
insulin resistance
LDL  low-density
lipoprotein
NHANES  National Health
and Nutrition Examination
Survey
TC  total cholesterol
TG  triglyceride
WHtR  waist/height ratiohe replicated measurements were used to determine blood
Demographic Data, Lipid Profile, Glycemic Profile, Inflammation, Blood Pressure, and Metabolic Syndrome by BMI and WHtR CategoryTable 1 Demographic Data, Lipid Profile, Glycemic Profile, Inflammation, Blood Pressure, and Metabolic Syndrome by BMI and WHtR Category
N
BMI <85%,
WHtR <0.5
BMI <85%,
WHtR 0.5–<0.6
BMI 85%–<95%,
WHtR <0.5
BMI 85%–<95%,
WHtR 0.5–<0.6
BMI >95%,
WHtR <0.5
BMI >95%,
WHtR 0.5–<0.6
BMI >95%,
WHtR >0.6
p
BMIz
p
WHtR
Demographic data
N 14,493 8,186 (57%) 441 (3%) 1,068 (7%) 852 (6%) 319 (2%) 2,173 (15%) 1,454 (10%) — —
Male 14,493 4,218 (52%) 82 (19%) 620 (58%) 295 (35%) 221 (69%) 1,177 (54%) 667 (46%) 0.001 0.001
Age (yrs) 14,493 12.4 4.0 14.1 4.2 11.9 3.6 13.8 4.0 11.2 3.3 12.2 3.7 13.8 3.6 0.001 0.001
Ethnicity 14,493 0.001 0.001
Non-Hispanic White 4,700 2,357 (29%) 237 (54%) 246 (23%) 401 (47%) 44 (14%) 796 (36%) 619 (43%)
Hispanic-Mexican American 765 414 (5%) 26 (6%) 50 (5%) 58 (7%) 13 (4%) 132 (6%) 72 (5%)
Hispanic-Other Hispanic 3,870 2,378 (29%) 134 (30%) 249 (23%) 248 (29%) 43 (14%) 512 (23%) 306 (21%)
Non-Hispanic Black 4,505 2,635 (32%) 27 (6%) 473 (44%) 117 (14%) 200 (63%) 650 (30%) 403 (28%)
Other 654 402 (5%) 17 (4%) 50 (5%) 28 (3%) 19 (6%) 83 (4%) 54 (4%)
BMI (kg/m2) 14,493 18.1 2.7 21.2 2.9 21.4 2.8 23.4 3.1 23.0 3.1 25.7 4.0 33.0 6.1 0.001 0.001
Waist (cm) 14,493 65.1 9.2 77.5 10.6 71.3 9.4 81.2 10.5 72.7 9.6 84.3 11.2 104.1 14.3 0.001 0.001
Waist percentile 90th percentile 0 (0%) 6 (1%) 1 (0%) 58 (7%) 3 (1%) 1,064 (49%) 1,380 (95%) 0.001 0.001
Lipid profile
Fasting 4,238 2,311 (30%) 145 (35%) 292 (29%) 253 (31%) 98 (32%) 632 (30%) 507 (36%) 0.46 0.92
TC (mmol/l) 12,396 4.11 0.74 4.25 0.86 4.19 0.72 4.30 0.79 4.13 0.75 4.32 0.81 4.44 0.90 0.001 0.001
TC (mg/dl) 12,396 159 29 164 33 162 28 166 31 159 29 167 31 171 35
Fasting TC (mmol/l) 3,876 4.11 0.73 4.26 0.72 4.13 0.63 4.31 0.81 4.17 0.84 4.37 0.87 4.48 0.86 0.04 0.001
Fasting TC (mg/dl) 3,876 159 28 164 28 159 24 166 31 161 32 169 34 173 33
TC classification* 12,396 0.09 0.001
Normal 4,709 (68%) 237 (64%) 590 (63%) 447 (60%) 183 (66%) 1,060 (56%) 657 (51%)
Borderline 1,726 (25%) 99 (27%) 279 (30%) 208 (28%) 73 (26%) 570 (30%) 389 (30%)
High 467 (7%) 36 (10%) 71 (8%) 85 (12%) 21 (8%) 257 (14%) 232 (18%)
HDL (mmol/l) 12,392 1.43 0.33 1.35 0.32 1.38 0.30 1.29 0.29 1.38 0.30 1.24 0.29 1.16 0.28 0.001 0.001
HDL (mg/dl) 12,392 55 13 52 12 53 12 50 11 53 12 48 11 45 11
Fasting HDL (mmol/l) 3,874 1.44 0.33 1.35 0.30 1.40 0.29 1.30 0.30 1.35 0.32 1.26 0.29 1.18 0.28 0.001 0.001
Fasting HDL (mg/dl) 3,874 56 13 52 12 54 11 50 12 52 12 49 11 46 11
Non-HDL (mmol/l) 12,392 2.68 0.69 2.91 0.82 2.80 0.69 3.01 0.75 2.76 0.72 3.08 0.82 3.28 0.88 0.01 0.001
Non-HDL (mg/dl) 12,392 103 27 112 32 108 27 116 29 107 58 119 32 127 34
Fasting non-HDL (mmol/l) 3,874 2.67 0.69 2.91 0.69 2.73 0.61 3.01 0.79 2.81 0.81 3.11 0.86 3.30 0.85 0.70 0.001
Fasting non-HDL (mg/dl) 3,874 103 27 112 27 105 24 116 31 108 31 120 33 127 33
Non-HDL classification† 12,392 0.92 0.001
Normal 5,273 (76%) 247 (66%) 637 (68%) 438 (59%) 203 (73%) 1,035 (55%) 575 (45%)
Borderline 1,215 (18%) 81 (22%) 217 (23%) 190 (26%) 54 (20%) 488 (26%) 367 (29%)
High 412 (6%) 44 (12%) 85 (9%) 112 (15%) 20 (7%) 363 (19%) 336 (26%)
HDL/TC ratio 12,392 0.35 0.08 0.32 0.08 0.34 0.08 0.31 0.07 0.34 0.08 0.29 0.08 0.27 0.07 0.66 0.001
Fasting TG (mmol/l) 2,594 0.81 0.38 0.95 0.36 0.84 0.62 1.10 0.54 0.93 0.55 1.13 0.59 1.48 1.39 0.43 0.001
Fasting TG (mg/dl) 2,594 72 34 84 32 74 55 97 48 82 49 100 52 131 123
Elevated TG‡ 42 (3%) 3 (3%) 8 (4%) 18 (12%) 6 (10%) 60 (16%) 69 (23%) 0.79 0.001
Continued on the next page
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ContinuedTable 1 Continued
N
BMI <85%,
WHtR <0.5
BMI <85%,
WHtR 0.5–<0.6
BMI 85%–<95%,
WHtR <0.5
BMI 85%–<95%,
WHtR 0.5–<0.6
BMI >95%,
WHtR <0.5
BMI >95%,
WHtR 0.5–<0.6
BMI >95%,
WHtR >0.6
p
BMIz
p
WHtR
Fasting TG/HDL ratio§ 2,593 0.61 0.38 0.76 0.39 0.66 0.69 0.93 0.61 0.84 0.73 1.00 0.70 1.41 1.60 0.33 0.01
Fasting LDL (mmol/l) 2,570 2.30 0.64 2.46 0.60 2.37 0.56 2.54 0.68 2.42 0.67 2.64 0.81 2.63 0.71 0.40 0.001
Fasting LDL (mg/dl) 2,570 89 25 95 23 92 22 98 26 93 26 102 31 102 27
Glycemic profile
Fasting glucose (mmol/l) 1,963 5.06 0.75 4.98 0.43 5.10 0.42 5.15 0.46 5.05 0.31 5.08 0.41 5.24 1.21 0.74 0.04
Fasting glucose (mg/dl) 1,963 91 14 90 8 92 8 93 8 91 6 92 7 94 22
Elevated glucose 12 (1%) 1 (1%) 3 (2%) 3 (2%) 0 (0%) 4 (2%) 11 (5%) 0.43 0.27
Fasting insulin (pmol/l) 1,933 55 26 73 43 69 26 82 47 84 35 105 60 146 91 0.002 0.001
Fasting insulin (IU/ml) 1,933 8 4 11 6 10 4 12 7 12 5 15 9 21 13
Elevated insulin¶ 29 (3%) 10 (12%) 6 (5%) 19 (15%) 6 (18%) 75 (30%) 130 (54%) 0.001 0.001
Hemoglobin A1c (%) 7,636 5.2 0.5 5.1 0.5 5.2 0.5 5.1 0.4 5.2 0.3 5.2 0.3 5.3 0.7 0.32 0.01
Elevated hemoglobin A1c 6.5% 16 (0%) 1 (0%) 1 (0%) 2 (0%) 0 (0%) 2 (0%) 15 (2%) 0.47 0.02
HOMA-IR 1,927 1.81 0.90 2.37 1.44 2.27 0.96 2.73 1.61 2.71 1.13 3.45 2.08 5.00 3.69 0.002 0.001
Elevated HOMA-IR 3.16 73 (7%) 16 (19%) 15 (11%) 39 (31%) 9 (27%) 116 (46%) 168 (69%) 0.001 0.001
Inflammation
C-reactive protein (mg/l) 11,795 0.0 (0.0–0.4) 0.1 (0.1–0.7) 0.0 (0.0–0.4) 0.1 (0.0–0.6) 0.1 (0.0–0.5) 0.1 (0.0–0.9) 0.3 (0.0–1.5) 0.002 0.001
Normal (0.7 mg/l) 6,381 (97%) 357 (96%) 880 (98%) 680 (96%) 241 (96%) 1,637 (93%) 995 (82%) 0.02 0.001
Mildly elevated (0.7–3.0 mg/l) 187 (3%) 16 (4%) 18 (2%) 27 (4%) 8 (3%) 105 (6%) 212 (18%)
Elevated (3.0 mg/l) 24 (0%) 1 (0%) 3 (0%) 4 (1%) 1 (0%) 11 (1%) 7 (1%)
AST (U/l) 7,525 22 (16–35) 21 (15–29) 22 (16–38) 22 (15–32) 23 (16–38) 22 (16–39) 22 (15–45) 0.16 0.002
Elevated AST 40 U/l 90 (2%) 5 (2%) 19 (4%) 9 (2%) 4 (3%) 46 (4%) 58 (6%) 0.002 0.77
ALT (U/l) 7,525 15 (10–27) 16 (10–30) 16 (10–30) 17 (10–36) 17 (10–31) 18 (12–43) 21 (12–68) 0.07 0.001
Elevated ALT 40 U/l 48 (1%) 5 (2%) 12 (2%) 18 (3%) 4 (3%) 60 (6%) 125 (14%) 0.14 0.001
Blood pressure
Systolic blood pressure (mm Hg) 11,597 105 10 106 9 108 10 108 10 109 11 110 10 114 11 0.001 0.001
Systolic blood pressure z-score 0.40 0.85 0.27 0.86 0.15 0.83 0.16 0.89 0.02 0.86 0.08 0.86 0.31 0.93 0.001 0.001
Diastolic blood pressure (mm Hg) 11,515 59 12 60 10 58 11 59 11 57 12 58 12 60 12 0.15 0.10
Diastolic blood pressure z-score 0.51 1.13 0.47 1.04 0.65 1.11 0.63 1.12 0.79 1.38 0.64 1.22 0.46 1.17 0.002 0.04
Hypertension 11,597 0.001 0.001
Normotension (90th percentile) 6,028 (95%) 338 (94%) 789 (95%) 672 (93%) 229 (91%) 1,590 (89%) 1,068 (82%)
Pre-hypertension (95th percentile) 204 (3%) 11 (3%) 30 (4%) 30 (4%) 16 (6%) 102 (6%) 109 (8%)
Stage 1 (95th percentile) 101 (2%) 7 (2%) 15 (2%) 17 (2%) 5 (2%) 77 (4%) 99 (8%)
Stage 2 (99th percentile) 13 (0%) 2 (1%) 1 (0%) 4 (1%) 2 (1%) 13 (1%) 25 (2%)
Metabolic syndrome# 1,901 1 (0%) 0 (0%) 1 (1%) 1 (1%) 0 (0%) 26 (10%) 76 (32%) 0.009 0.001
Values are n (%) or mean SD. N the number of subjects for which values for the given variable are available. P values from regression models testing for the independent effect of body mass index (BMI) (p BMIz) and waist/height ratio (p WHtR) adjusted for age at testing
and sex. *Total cholesterol (TC) classification: normal4.4mmol/l (170mg/dl); borderline4.4 to5.2mmol/l (170 to200mg/dl); high5.2mmol/l (200mg/dl). †Non–high-density lipoprotein (HDL) cholesterol classification: normal3.10mmol/l (120mg/dl);
borderline 3.10 to 3.75 mmol/l (120 to 145 mg/dl); high 3.75 mmol/l (145 mg/dl). ‡Elevated triglycerides (TG): 1.7 mmol/l (150 mg/dl). §Ratio from SI units. Elevated glucose: 6.1 mmol/l (110 mg/dl). ¶Elevated insulin: 118 pmol/l (17 IU/ml).
#National Cholesterol Education Program Adult Treatment Panel (NCEP-ATP) III pediatric definition: 3 or more of: 1) waist circumference 90th percentile for age and sex; 2) fasting TG 1.25 mmol/l (110 mg/dl); 3) HDL 1.03 mmol/l (40 mg/dl); 4) blood pressure
90th percentile for age, height, and sex; and 5) fasting glucose 5.6 mmol/l (100 mg/dl).
ALT  alanine aminotransferase; AST  aspartate aminotransferase; LDL  low-density lipoprotein. 745
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Cardiometabolic Risk in Children August 20, 2013:742–51pressure (23). Systolic and diastolic blood pressure were
converted to age, sex, and height-based z-scores, which
were used to classify each subject as pre-hypertensive (90th
to95th percentile), stage 1 hypertensive (95th to99th
percentile), or stage 2 hypertensive (99th percentile) (31).
Metabolic syndrome. Metabolic syndrome was defined
according to the National Cholesterol Education Program
Adult Treatment Panel III pediatric definition (32,33),
which requires the presence of 3 or more of the following:
1) waist circumference 90th percentile for age and sex
34); 2) fasting TG 1.25 mmol/l (110 mg/dl); 3) HDL
1.03 mmol/l (40 mg/dl); 4) blood pressure 90th
ercentile for age, height and sex; and 5) fasting glucose
5.6 mmol/l (100 mg/dl).
ata analysis. Data are reported as means with SD,
edian with 5th and 95th percentiles, and frequencies as
ppropriate. All continuous variables with the exception of
RP level (which was categorized) had a distribution close
nough to normal to be treated as normal. Linear, logistic,
nd ordinal logistic regression models (as appropriate),
djusted for age at testing and sex, were used to determine
he relative contribution of WHtR and BMI z-score (mod-
led as continuous variables) on cardiometabolic risk factors.
eported p values represent the statistical significance of the
ontribution of each element (WHtR or BMI z-score)
hile adjusting for the other one. Additionally, linear and
ogistic regression models were also created with the normal
MI percentile category (85%) and WHtR 0.5 as the
eference category and comparing all other WHtR/BMI
ercentile category combinations. These models were also
sed to determine the effect of WHtR category within BMI
ercentile categories with WHtR 0.5 as the reference
ategory. An interaction term was used to determine the
ifference between male and female subjects in regard to the
ssociation between worsening cardiometabolic risk factors
nd increased adiposity. We opted not to perform a
eighted analysis, despite the weighted sample strategy used
y NHANES, because our objective was to find associations
t an individual level and not to report population estimates.
s such any reported prevalence in this study should not be
aken as representing national estimates. All statistical
nalyses were performed with SAS statistical software (ver-
ion 9.3, SAS Institute, Cary North Carolina).
esults
ata were available for 14,493 subjects (age range 5 to 18
ears, 50% male, 4,238 [31%] with fasting blood work).
emographic data, lipid profile, glycemic profile, inflam-
ation, blood pressure, and metabolic syndrome stratified
y BMI percentile and WHtR categories are reported in
able 1. Increased BMI category was universally associated
ith increased cardiometabolic risk factors, including all
lements of lipid and glycemic profile, inflammation, blood
ressure, and metabolic syndrome. With few exceptions,HtR was found to further stratify cardiometabolic risk factor fevels beyond BMI percentile category alone (Table 1). Pa-
ients with the highest level of adiposity (WHtR 0.6 and
MI 95th percentile) were found to have a high proportion
f abnormal levels in cardiometabolic risk factors.
Mean values for selected cardiometabolic risk factors
Fig. 1) and proportion of abnormal findings (Fig. 2) across
MI percentile and WHtR categories, adjusted for age and
ex, are presented in Figures 1 and 2. For most variables,
ncreased BMI percentile category was associated with
ncreased cardiovascular risk factors. Elevated WHtR cate-
ory, regardless of BMI percentile category was associated
ith increased cardiometabolic risk factors, whereas high
MI percentile category but low WHtR category had
ardiometabolic risk factor levels approaching that of the
ormal BMI category population. The association be-
ween increased adiposity and cardiometabolic risk fac-
ors was mediated by sex (Table 2). Although increased
diposity was associated with increased cardiometabolic
isk in both sexes, the increase was proportionally more
arked in male subjects than in female subjects. A
ignificant proportion of obese subjects with a WHtR
0.6 had abnormal cardiometabolic risk factor levels
18% to 78%, depending on the cardiometabolic risk
actor) (Fig. 2). Those patients with both elevated BMI
ategory and elevated WHtR category were at signifi-
antly higher risk for all measures at a higher level than
xpected by either measure alone, suggesting a distinct
athological process at that level of adiposity.
iscussion
ur study sought to investigate the role of WHtR in the
ardiometabolic risk assessment of normal, overweight, and
bese children categorized by BMI percentile category. We
ound that an increased WHtR category was associated with
orsened cardiometabolic risk and an increased frequency
f abnormal cardiometabolic risk factor levels. Subjects
ategorized as overweight and obese by BMI percentile with
WHtR 0.5 had a cardiometabolic risk that was ap-
roaching that of subjects with a normal BMI percentile
ategory. This is of particular importance for overweight
ubjects, because 55% had a WHtR 0.5, indicating that a
arge proportion of overweight children might have a
ardiometabolic risk that is not as high as previously
erceived. Ninety-seven percent of subjects with a normal
MI category had a WHtR 0.5, indicating that subjects
ith normal BMIs are unlikely to have elevated levels of
entral adiposity. Conversely, the majority of obese subjects
ad an elevated waist measure.
linical utility of the WHtR. Because BMI measurement
annot differentiate between fat and fat-free mass or serve as
n indicator of the anatomical distribution of mass, an in-
reased BMI might not reflect increased central adiposity.
aist measures, conversely, are an effective indicator of central
at distribution, serving as a strong marker of cardiometabolic
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elected to focus our statistical analysis on the utility of
WHtR in further specifying cardiometabolic risk. In the
previous work of our group (24), WHtR and waist
circumference percentile showed very similar associations
with cardiometabolic risk in the normal, overweight, and
obese population. The WHtR might be advantageous,
because it is a convenient marker that does not require
conversion to z-scores or percentiles (18,19,21,22). It has
been previously suggested that a WHtR of 0.5 might
serve as a consistent threshold of increased risk across sex
and ethnicity, from childhood to adulthood, and might
Figure 1 Mean Values of Selected Cardiometabolic Risk Facto
Reported are mean values adjusted for age and sex. Normal: body mass index (BM
ratio (WHtR) 0.5; dark pink: WHtR 0.5 to 0.6; black: WHtR 0.6. First row of
Second row of p values represent individual group comparison within each BMI ca
model assessment of insulin resistance; LDL  low-density lipoprotein.be easier for patients and families to understand (19,37),thus creating the potential for an important public health
message of “keep your waist circumference half your
height.”
Although strong associations were observed between
increasing WHtR and worsening cardiometabolic risk fac-
tor levels in both male and female subjects, these associa-
tions seemed stronger in male subjects. Post-pubertal female
subjects have a predisposition for gluteofemoral fat deposi-
tion, an anatomic area of adiposity that has been shown to
play a protective role in the development of cardiometabolic
risk (38). Therefore, an increase in the WHtR in some
female subjects might be potentially offset by the presence of
ross BMI and WHtR Categories
5%; Overweight: BMI 85 to 95%; Obese: BMI 95%; Light pink: waist/height
es represent individual group comparison versus normal BMI and WHtR 0.5.
versus WHtR 0.5. HDL  high-density lipoprotein; HOMA-IR  homeostaticrs Ac
I) 8
p valu
tegoryincreased gluteofemoral fat relative to male subjects. To the
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shown and needs to be further explored.
Review of previous published data. Although guidelines
from the major American, British, and Canadian medical
associations acknowledge the potential added benefits of
using waist measures, they are not in full agreement with
respect to its use in screening the pediatric population
(39–41). The present study shows the incorporation of
waist measures improves cardiometabolic risk specification
among children, suggesting that waist measures should be
considered in routine pediatric screening.
Our group recently assessed the association of waist
Figure 2 Proportion of Elevated Selected Cardiometabolic Risk
Reported are proportions of patients with elevated cardiometabolic risk factors (cr
Obese: BMI 95%; light pink: WHtR 0.5; dark pink: WHtR 0.5 to 0.6; black:
BMI and WHtR 0.5. Second row of p values represent individual group comparis
Program Adult Treatment Panel III definition was used for metabolic syndrome. Abmeasures with non-fasting lipid and blood pressure screen-ing assessments of 4,384 adolescents enrolled in the Heart
Niagara, Inc., Healthy Heart Schools Program in the
Niagara Region of Ontario, Canada (24). Increasing WHtR
categories corresponded with a worsening non-fasting lipid
profile and increased odds of a higher degree of hyperten-
sion, with the greatest associations occurring in obese
subjects. Overweight and obese subjects with WHtRs 0.5
were found to have significantly different mean lipid values
relative to normal subjects. This study was limited, because
it assessed only 14- to 15-year-olds through the use of
non-fasting lipids and blood pressure data and did not
include inflammatory markers. Our present study similarly
ors Across BMI and WHtR Categories
mbedded in y-axes legends). Normal: BMI 85%; Overweight: BMI 85 to 95%;
0.6. First row of p values represent individual group comparison versus normal
in each BMI category versus WHtR 0.5. The National Cholesterol Education
ions as in Figure 1.Fact
iteria e
WHtR
on with
breviatshowed an increased WHtR to be associated with increased
or each
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and obese subjects with a WHtR 0.5 had a cardiometa-
bolic risk approaching that of subjects with a normal BMI.
Obesity in childhood is associated with an increased
prevalence of other cardiometabolic risk factors (3,6). Fur-
thermore, cardiometabolic risk factors in childhood track
into adulthood (2,4), posing a significant public health
concern. Our study of 14- to 15-year-olds in Ontario,
Canada found an increased prevalence of elevated cardio-
metabolic risk factors in obese children with a WHtR0.6.
For example, 25% had elevated non-HDL levels, and 17%
had stage 1 or 2 hypertensive blood pressure levels (24).
Two other school-based studies have shown similar results
(42,43). In the present study, approximately 10% of subjects
were obese and had a WHtR 0.6. This group had an
increased prevalence of elevated cardiometabolic risk factor
levels (Fig. 2). For example, 18% had an elevated CRP, 32%
met the modified criteria for metabolic syndrome, and 69%
had an elevated HOMA-IR index (Fig. 2). In contrast,
overweight and obese subjects with WHtR 0.5 did not
tend to have a significantly increased prevalence of abnormal
cardiometabolic risk factor levels relative to subjects with a
normal BMI. Given that 55% of subjects in our study
categorized as overweight by BMI had a WHtR 0.5, the
use of WHtR in pediatric screening might serve to further
alert the clinician to evaluate for additional cardiometabolic
risk factors, particularly in overweight patients.
A number of studies have found waist measures to
provide an added benefit in the assessment of cardiometa-
bolic risk for children categorized by BMI (18,20,44–46).
However, many of these studies were derived from subject
populations that are not representative of the American
pediatric population, either through the use of data from the
Bogalusa Heart Study (18,19,45,46), a Caucasian popula-
Interaction Between Sex and Association Between Adiposity and CTable 2 Interaction Between Sex and Association Between Ad
Outcome
Male
EST (SE) p V
TC (mmol/l) 0.186 (0.012) 0.
HDL (mmol/l) 0.141 (0.005) 0.
Non-HDL (mmol/l) 0.327 (0.012) 0.
HDL/TC ratio 0.045 (0.001) 0.
Fasting TG (mmol/l) 0.320 (0.024) 0.
Fasting TG/HDL ratio 0.399 (0.028) 0.
Fasting LDL (mmol/l) 0.211 (0.023) 0.
Fasting glucose (mmol/l) 0.101 (0.017) 0.
Fasting insulin (pmol/l) 43.6 (1.7) 0.
Hemoglobin A1c (%) 0.055 (0.009) 0.
HOMA-IR 1.734 (0.078) 0.
C-reactive protein (mg/l) 0.108 (0.007) 0.
AST (U/l) 1.012 (0.189) 0.
ALT (U/l) 6.580 (0.259) 0.
Systolic blood pressure z-score 0.330 (0.014) 0.
Reported is the change in outcomes (unit provided) for each increase of 0.1 in WHtR separately f
EST  parameter estimate; SE  standard error; other abbreviations as in Table 1.tion (20), or a biracial population (44). The present study,through the use of NHANES data, is derived from a large
and diverse subject population. In addition, the present
study incorporated a wide range of fasting and non-fasting
cardiometabolic risk factors, including inflammatory mark-
ers and a modified definition for metabolic syndrome.
Adiposopathy. To the best our knowledge, previous stud-
ies assessing the role of waist measures in children catego-
rized by BMI have not incorporated surrogate markers of
inflammation such as CRP and liver transaminases. The
prevalence of increased cardiometabolic risk factor levels in
children with increased central adiposity might be attributed
to the inflammatory state of adiposopathy (17). Adiposopa-
thy refers to the presence of pathological, anatomic, and/or
functional adipose tissue disturbances that are promoted by
a positive caloric balance in genetically and environmentally
susceptible individuals. This results in adverse endocrine
and immune responses that might promote cardiovascular
disease or worsen metabolic disease (17). In such an
inflammatory state, CRP might be increased both through
direct production by adipocytes and through increased
hepatic production (47–49). Adiposopathy is more likely to
develop in the setting of excessive central or visceral
adiposity (17). This might help explain the large discrep-
ancy in the prevalence of metabolic syndrome and ele-
vated CRP and liver transaminases among obese children
with a high WHtR relative to those with a lower WHtR
found in the present study. Therefore, obese children
with increased central adiposity but without any other
diagnosed cardiometabolic disease might not be “healthy”
as previously perceived due to the underlying pro-
inflammatory state of adiposopathy.
Study limitations. The primary limitation of this study
was that only associations but not causality can be inferred,
given its cross-sectional design. The statistical analysis
metabolic Risky and Cardiometabolic Risk
Female
Interaction
p ValueEST (SE) p Value
0.113 (0.012) 0.001 0.001
0.112 (0.005) 0.001 0.001
0.235 (0.012) 0.001 0.001
0.036 (0.001) 0.001 0.001
0.225 (0.018) 0.001 0.001
0.258 (0.020) 0.001 0.001
0.125 (0.022) 0.001 0.004
0.059 (0.032) 0.06 0.21
34.2 (1.6) 0.001 0.001
0.045 (0.008) 0.001 0.41
1.467 (0.086) 0.001 0.01
0.172 (0.009) 0.001 0.001
0.144 (0.166) 0.39 0.001
2.865 (0.242) 0.001 0.001
0.319 (0.013) 0.001 0.63
sex. P values at the far right represent the statistical significance of the interaction.ardioiposit
alue
001
001
001
001
001
001
001
001
001
001
001
001
001
001
001involved the categorization of BMI and WHtR according to
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results. It is difficult to assess the independence of the
WHtR relationship within BMI categories to BMI gradient
within BMI categories itself, because both variables are
highly collinear. Although WHtR seems to further specify
cardiometabolic risk in this study, longitudinal studies are
required to track its relationship to cardiometabolic risk
throughout childhood and into adulthood. Pubertal stage
information of the subjects was not considered, and the data
were not stratified on the basis of ethnicity or sex. Although
pubertal stage and ethnicity might confer to different
absolute levels of cardiometabolic risk, there is no indication
that the associations with increased WHtR within each
BMI category would vary. Further studies might be war-
ranted to specifically address variations on the basis of these
factors.
Conclusions
The WHtR seems to further specify the cardiometabolic
risk assessment of overweight and obese children. A
significant proportion of obese subjects with a high
WHtR had abnormal cardiometabolic risk factor levels
and met the criteria for metabolic syndrome. Overweight
and obese children with a low WHtR seem to have a
cardiometabolic risk that approaches that of normal BMI
children. Given that most overweight subjects had a low
WHtR, WHtR measurement might be a particularly
useful tool in this population, helping the clinician
further stratify cardiometabolic risk. The WHtR seems to
be an important discriminating measurement in the
cardiometabolic risk assessment of children and should
thus be included as part of routine pediatric screening of
overweight and obese children.
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